Qualifying Therapeutic Discovery Project Grants for the State of Oregon
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| 13therapeutics, Inc | Commercialization of Novel Therapeutic (P13) for Treatment of Inflammatory Diseases | $ 244,479.24 | |
| Artielle Immuno Therapeutics, Inc. | Development of a T Cell Specific Drug Against Multiple Sclerosis | $ 244,479.24 | |
| Bioject Medical Technologies, Inc. | Dose Sparing Needle-free Injection Delivery Systems | $ 244,479.25 | |
| Blacktoe Medical III, Inc | Miniaturized Finger-Wearable Ultarsound Transducer | $ 244,479.24 | |
| Calypte Biomedical Corp & Sub | Aware 2, A Rapid Test for Antibodies Against HIV-1/2 in Oral Fluid | $ 73,331.49 | $ 171,147.76 |
| Cascade Prodrug Inc | Anti-cancer therapeutics targeting tumor hypoxia | $ 244,479.25 | |
| Chemica Technologies, Inc. | Agent to Enhance Tumor Radiometal Uptake | $ 45,708.50 | $ 16,852.00 |
| DesignMedix, Inc | Dual-action drugs to overcome drug resistance in parasitic and bacterial disease | $ 152,186.50 | $ 92,292.74 |
| Electrical Geodesics, Inc. | Dense Array Electroencephalography (EEG) for Neurosurgical Planning in Epilepsy | $ 244,479.25 | |
| Epley Medical Inc. Dba Vesticon | Device of New Diagnosis and treatment of Benign Paroxysmal Positional Vertigo | $ 149,875.00 | $ 94,604.25 |
| HOME DIALYSIS PLUS, LTD. | Development of Novel Portable Nocturnal Hemodialysis System | $ 51,809.00 | $ 192,670.25 |
| Inovise Medical, Incorporated | Cardiopulmonary Holder | $ 244,479.24 | |
| Mitosciences Inc | MET3D | $ 244,479.25 | |
| Molecular MD Corp | Molecular Diagnostics c-KIT Cancer Gene Mutation Assay for Metastatic Melanoma patients | $ 103,615.00 | $ 140,864.25 |
| MolecularMD Corp | Molecular Diagnostics standardized BCR-ABL cancer gene quantization | $ 244,479.25 | |
| MolecularMD Corp | Molecular Diagnostics EGFR T790M Cancer Gene Mut Assy for relapsing NSCLC patients | $ 103,615.00 | $ 140,864.25 |
| MolecularMD Corp. | Molecular Diagnostics b-RAF V600E Cancer gene Mutation Assay for metatastic melanoma | $ 103,615.00 | $ 140,864.25 |
| Najit Technologies, Inc. | Development and optimization of dual-detection diagnostics | $ 244,479.24 | |
| Najit Technologies, Inc. | Development of a novel hydrogen peroxide-based vaccine platform | $ 183,931.19 | $ 60,548.05 |
| Pulse Health LLC | Breath Aldehyde Measurement System for the Quantitative Determination of Oxidative Stress | $ 244,479.25 | |
| River Point LLC, DBA Riverpoint Medical | Cancer Detection and Radiation Delivery Devices | $ 201,866.98 | $ 42,612.27 |
| Sedia Biosciences Corporation | Rapid Oral Fluid HIV Test | $ 10,279.00 | $ 38,421.00 |
| Sedia Biosciences Corporation | Novel Collection Devices | $ 4,125.00 | $ 8,825.00 |
| Tree Star Inc | FlowDx: Clinical CytometryAnalysis Software with Automated Gating | $ 70,507.00 | $ 81,535.00 |
| UbiVac LLC | New Cancer Vaccine Technology Based on Dribbles Produced by Tumor Cells | $ 15,196.39 | $ 229,282.86 |
| Yainax Medical, LLC | Microfluidics Transtymapanic Delivery System for Controlled Delivery of Drugs to Inner Ear | $ 37,000.00 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
